Childhood nail psoriasis: A useful treatment with tazarotene 0.05%

Laura Diluvio; Elena Campione; Evelin J. Paternò; Cristina Mordenti; Maya El Hachem; Sergio Chimenti

doi:10.1111/j.1525-1470.2007.00421.x

Childhood nail psoriasis: A useful treatment with tazarotene 0.05%

Laura Diluvio, Elena Campione, Evelin J. Paternò, Cristina Mordenti, Maya El Hachem, Sergio Chimenti

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article

Abstract

Nail psoriasis occurs in 7% to 40% of children, with a similar pattern of clinical presentation to that of adults. In 0.6% to 2.3% of the patients nail changes appear as the only sign of the disease, preceding other skin and articular involvement. No pediatric clinical trials are available yet, but considering the successful use of tazarotene for nail dystrophy therapy in adults, we chose this drug to treat a child.

Original language	English
Pages (from-to)	332-333
Number of pages	2
Journal	Pediatric Dermatology
Volume	24
Issue number	3
DOIs	https://doi.org/10.1111/j.1525-1470.2007.00421.x
Publication status	Published - May 2007

Fingerprint

ASJC Scopus subject areas

Dermatology
Pediatrics, Perinatology, and Child Health

Cite this

Diluvio, L., Campione, E., Paternò, E. J., Mordenti, C., Hachem, M. E., & Chimenti, S. (2007). Childhood nail psoriasis: A useful treatment with tazarotene 0.05%. Pediatric Dermatology, 24(3), 332-333. https://doi.org/10.1111/j.1525-1470.2007.00421.x

@article{d726bf9b201140ceb6958f10b2e0f8ea,

title = "Childhood nail psoriasis: A useful treatment with tazarotene 0.05%",

abstract = "Nail psoriasis occurs in 7% to 40% of children, with a similar pattern of clinical presentation to that of adults. In 0.6% to 2.3% of the patients nail changes appear as the only sign of the disease, preceding other skin and articular involvement. No pediatric clinical trials are available yet, but considering the successful use of tazarotene for nail dystrophy therapy in adults, we chose this drug to treat a child.",

author = "Laura Diluvio and Elena Campione and Patern{\`o}, {Evelin J.} and Cristina Mordenti and Hachem, {Maya El} and Sergio Chimenti",

year = "2007",

month = may

doi = "10.1111/j.1525-1470.2007.00421.x",

language = "English",

volume = "24",

pages = "332--333",

journal = "Pediatric Dermatology",

issn = "0736-8046",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Childhood nail psoriasis

T2 - A useful treatment with tazarotene 0.05%

AU - Diluvio, Laura

AU - Campione, Elena

AU - Paternò, Evelin J.

AU - Mordenti, Cristina

AU - Hachem, Maya El

AU - Chimenti, Sergio

PY - 2007/5

Y1 - 2007/5

N2 - Nail psoriasis occurs in 7% to 40% of children, with a similar pattern of clinical presentation to that of adults. In 0.6% to 2.3% of the patients nail changes appear as the only sign of the disease, preceding other skin and articular involvement. No pediatric clinical trials are available yet, but considering the successful use of tazarotene for nail dystrophy therapy in adults, we chose this drug to treat a child.

AB - Nail psoriasis occurs in 7% to 40% of children, with a similar pattern of clinical presentation to that of adults. In 0.6% to 2.3% of the patients nail changes appear as the only sign of the disease, preceding other skin and articular involvement. No pediatric clinical trials are available yet, but considering the successful use of tazarotene for nail dystrophy therapy in adults, we chose this drug to treat a child.

UR - http://www.scopus.com/inward/record.url?scp=34249779263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249779263&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1470.2007.00421.x

DO - 10.1111/j.1525-1470.2007.00421.x

M3 - Article

C2 - 17542899

AN - SCOPUS:34249779263

VL - 24

SP - 332

EP - 333

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 3

ER -

Access to Document

10.1111/j.1525-1470.2007.00421.x